New NK cell engaging immunotherapy approaches to target and potentially treat recalcitrant ovarian cancer

by

The Wistar Institute’s David B. Weiner and collaborators have engineered novel monoclonal antibodies that engage natural killer (NK) cells through a unique surface receptor that activates the immune system to fight against cancer.

Leave A Comment

Your email address will not be published. Required fields are marked *